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1. Introduction & Objectives 
2. Patients & Methods 
 
 
Reference: Colin P, Eleveld D.J., Struys M.M.R.F, et al. Moxifloxacin dosing in post-bariatric surgery patients: another nail in the coffin of the “one dose fits all paradigm”. J Antimicrob Chemother Under review     
Roux-en-Y gastric bypass surgery is the most commonly performed 
procedure for the treatment of morbid obesity. This anatomical alteration 
may affect the absorption and, consequently, the pharmacokinetic profile of 
oral drugs, possibly hampering therapeutic efficacy.  
This study aims to (i) describe the pharmacokinetic variability of 
moxifloxacin concentrations in this cohort of healthy volunteers who have 
undergone gastric bypass using a population pharmacokinetic model 
and (ii) to assess the expected probability of target attainment (PTA) by 
MIC against a hypothetical Streptococcus pneumonia infection. 
Our study clearly emphasises the need for an individualized dosing of moxifloxacin in this patient population. Furthermore, throughout our PK-PD 
simulation study it became apparent that the development of a model based dosing regimen for moxifloxacin is hampered by the current discussion on 
which PK-PD target value to pursue when optimizing patient moxifloxacin therapy. 
1De Smet J, Colin P, De Paepe P, et al. Oral bioavailability of moxifloxacin after Roux-en-Y gastric bypass surgery. J Antimicrob Chemother 2012; 67: 226-9. 
3. Results (Pop-PK model) 
4. Conclusion 
Figure 1: Observed moxifloxacin plasma-concentration time profiles after oral dosing. 
3. Results (PK-PD simulation) 
In this modelling and simulation study we used data from a randomized 
cross-over trial on moxifloxacin pharmacokinetics previously published1.  
In this trial, twelve volunteers, who had previously undergone bariatric 
surgery, received 2 single standard doses (intravenous and oral) of 
400mg moxifloxacin administered on 2 occasions separated by a 
washout period of 1 week. Serial venous blood samples were drawn up 
to 72h after dosing and moxifloxacin plasma levels were measured by a 
validated high performance liquid chromatographic method with 
fluorescence detection. Population compartmental modelling and PK-PD 
simulations were performed using NONMEM®.  
Table 1: Population parameter 
estimates of the final pharmacokinetic 
model and the associated 95% 
bootstrap confidence intervals 
calculated on 100 bootstrap samples. All 
model parameters except ka were 
centered for a typical subject with a LBM 
of 60 kg. 
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Figure 2: Predicted AUIC values after a standard 400mg oral dose versus the 
theoretical Streptococcus pneumonia MIC-values.  
 
Simultaneously the AUIC cut-off values as proposed in literature are shown.  
long dashes: AUICTotal = 100 target for bacterial eradication 
short dashed lines: AUICUnbound = 100; target for suppression of bacterial resistance 
formation. 
Figure 3: Predicted AUIC values for subjects with a LBM of 42 kg (open squares) and 
78 kg (solid squares) after a standard 400mg oral dose versus the theoretical 
Streptococcus pneumonia MIC-values.  
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